Question explored with the scientific record
Is the pneumococcal vaccine effective?
The pneumococcal vaccine works for some people against some outcomes, but the evidence is uneven and the benefit is often smaller than advertised.
The strongest evidence comes from a double-blind, placebo-controlled trial in 1,006 Japanese nursing home residents. The 23-valent polysaccharide vaccine (PPV23) cut all-cause pneumonia from about 21 in 100 to about 13 in 100 over two years, and pneumococcal pneumonia from about 7 in 100 to about 3 in 100 [1]. No one who got the vaccine and still got pneumococcal pneumonia died from it, compared to 13 deaths in the placebo group [1]. That is a real benefit in a frail, high-risk population.
But the picture changes for healthier older adults. A large Finnish cohort of 26,925 people aged 65 and older found that adding PPV23 to the flu shot gave no extra protection against pneumonia or pneumococcal pneumonia [3]. The relative risk for pneumonia was 1.2, meaning the vaccine group actually had slightly more cases [3]. A 2014 South Korean study of 2,262 patients with flu-like illness found the pneumococcal vaccine was "not effective" at preventing pneumonia or hospitalization [2]. A 2021 review of the CAPiTA trial, the largest randomized trial of the 13-valent conjugate vaccine (PCV13) in older adults, found only a small, non-significant reduction in lower respiratory tract infections in primary care [8].
For children, the conjugate vaccines (PCV7, PCV10, PCV13) have reduced invasive disease from the serotypes they target. In Denmark, PCV7 cut invasive pneumococcal disease by 54% in children under 2 [5]. In Finland, PCV10 reduced it by 78% in vaccinated children [7]. But serotype replacement is real: non-vaccine serotypes increase, and the overall decline is often modest [6]. In Taiwan, overall IPD dropped 38% after vaccine introduction, but serotype 19A, not covered by PCV7, rose from 0.5% to 11.5% of cases [4].
| Population | Outcome | Vaccine | Result |
|---|---|---|---|
| Nursing home residents (Japan) | All-cause pneumonia | PPV23 | 12.5% vs 20.6% (placebo) [1] |
| Community elderly (Finland) | Pneumonia | PPV23 + flu vs flu alone | No benefit (RR 1.2) [3] |
| Children <2 (Denmark) | Invasive disease | PCV7 | 54% reduction [5] |
| Children <5 (Finland) | Invasive disease | PCV10 | 78% reduction [7] |
| Adults 65+ (Netherlands) | LRTI in primary care | PCV13 | Non-significant 3.8% reduction [8] |
The evidence is funded by government grants and public health agencies, not manufacturers, for the key trials [1][3]. But the literature has a structural problem: most studies compare vaccinated to unvaccinated in observational designs, not randomized trials. The one large randomized trial in healthy older adults (CAPiTA) showed modest effects that did not reach significance for most real-world outcomes [8]. The PPV23 meta-analysis from 2024 found no reduction in all-cause mortality and only a reduction in pneumonia-related death [9].
My call: the pneumococcal vaccine reduces serious disease in high-risk groups like nursing home residents and young children, but for healthy adults and older people living independently, the benefit is small and inconsistent. The evidence does not support universal vaccination for everyone over 65. Confidence: moderate.
Sources used 9
-
Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial
A double-blind, randomized, placebo-controlled trial in Japanese nursing home residents found that the 23-valent pneumococcal polysaccharide vaccine reduced both all-cause pneumonia and pneumococcal pneumonia and decreased deaths due to pneumococcal pneumonia, with no deaths in …
DOI: 10.1136/BMJ.C1004 -
Prospective Cohort Study on the Effectiveness of Influenza and Pneumococcal Vaccines in Preventing Pneumonia Development and Hospitalization
This study evaluates the effectiveness of influenza and pneumococcal vaccines in preventing pneumonia and hospitalization among patients with influenza-like illness during the 2013-2014 influenza season in South Korea, finding that influenza vaccination significantly reduces pne…
DOI: 10.1128/cvi.00673-14 -
Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older
A large Finnish prospective cohort study evaluated whether coadministering the 23-valent pneumococcal polysaccharide vaccine with the influenza vaccine provides incremental protection against pneumonia, pneumococcal pneumonia, and pneumococcal bacteraemia in people aged 65 years…
DOI: 10.1016/s0264-410x(99)00069-9 -
Impact of pneumococcal vaccines on invasive pneumococcal disease in Taiwan
This study evaluates the impact of pneumococcal vaccines on the incidence and characteristics of invasive pneumococcal disease (IPD) in Taiwan from 2000 to 2008, revealing a significant decrease in IPD incidence but no change in fatality rates, alongside a concerning rise in ser…
DOI: 10.1007/s10096-010-0873-7 -
Impact of pneumococcal vaccination in Denmark during the first 3 years after PCV introduction in the childhood immunization programme
This study evaluates the impact of the 7-valent pneumococcal conjugate vaccine (PCV7) introduced in Denmark in 2007, demonstrating a significant decrease in invasive pneumococcal disease (IPD) incidence and related mortality in vaccinated children, while also noting an increase …
DOI: 10.1016/j.vaccine.2012.03.060 -
Changing epidemiology of invasive pneumococcal disease following increased coverage with the heptavalent conjugate vaccine in Navarre, Spain
This study analyzes changes in invasive pneumococcal disease (IPD) incidence and serotype distribution in Navarre, Spain, after increased coverage with the 7-valent pneumococcal conjugate vaccine (PCV7), finding a substantial drop in IPD from vaccine serotypes but a rise in non-…
DOI: 10.1111/j.1469-0691.2009.02904.x -
Long-term impact of 10-valent pneumococcal conjugate vaccination on invasive pneumococcal disease among children in Finland
This study evaluates the long-term impact of the 10-valent pneumococcal conjugate vaccine (PCV10) on invasive pneumococcal disease (IPD) among children in Finland, demonstrating a significant reduction in IPD incidence among vaccinated children and a sustained indirect effect on…
DOI: 10.1016/j.vaccine.2018.03.001 -
Effects of 13-valent pneumococcal conjugate vaccination of adults on lower respiratory tract infections and antibiotic use in primary care: secondary analysis of a double-blind randomized placebo-controlled study
Secondary analysis of the CAPiTA randomized trial in community-dwelling adults aged 65 and older shows PCV13 vaccination led to non-significant, small reductions in vaccine-type CAP, non-CAP LRTI, and LRTI-related antibiotic use in primary care, with no reduction in total antibi…
DOI: 10.1016/j.cmi.2020.09.011 -
Mortality reduction with 23-valent pneumococcal polysaccharide vaccine: a systematic review and meta-analysis
This systematic review and meta-analysis evaluated the effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPV23) in reducing all-cause and pneumonia-related mortality among adults, finding no significant reduction in all-cause mortality but a significant reducti…
DOI: 10.1186/s41479-024-00149-5